VFA
NKTR icon

Virtus Fund Advisers’s Nektar Therapeutics NKTR Stock Holding History

Virtus Fund Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$1.01M Buy
+1,126
New +$666K 0.01% 284
2014
Q3 		– Sell
-722
Closed -$139K – 1652
2014
Q2 		$139K Buy
+722
New +$128K ﹤0.01% 1172

Other funds holding NKTR

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtus Fund Advisers's NKTR Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Nektar Therapeutics (NKTR) in Q4 2017: 1,126 shares worth $1.01M. The stake represents 0.01% of the portfolio and ranks #284 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in NKTR as recently as Q2 2014.

Virtus Fund Advisers first reported a position in NKTR in Q2 2014 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold NKTR as of Q4 2017.

  • Virtus Fund Advisers held 1,126 shares of Nektar Therapeutics worth $1.01M as of Q4 2017.
  • Nektar Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • Nektar Therapeutics made up 0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #284 holding.
  • Virtus Fund Advisers first reported a position in Nektar Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.